Novacea

Richmond, United States Founded: 2001 • Age: 25 yrs Listed Acquired By Transcept Pharmaceuticals
Serotonin inhibitor drugs for cancer are developed by Novacea.

About Novacea

Novacea is a Healthcare company based in Richmond (United States) founded in 2001, and was acquired by Transcept Pharmaceuticals in September 2008. Serotonin inhibitor drugs for cancer are developed by Novacea. Novacea has raised $35 million across 1 funding round from investors including Apax Partners, Transcept Pharmaceuticals and Domain Associates. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.

Company details

Novacea Pharmaceuticals was established in 2001 in Richmond, United States, within the biotechnology sector. Focus was placed on in-licensing and advancing cancer therapies, including Asentar in phase 3 trials for androgen-independent prostate cancer and phase 2 for advanced pancreatic cancer, as well as AQ4N in phase 1b2a trials for glioblastoma multiforme. Acquisition by Transcept Pharmaceuticals occurred in September 2008, leading to a merger.

Operational Areas
Key Metrics

Funding Insights of Novacea

Novacea has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series C round of $35 million completed in January 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $35M
  • Total Rounds 1
  • Last Round Series C β€” $35M
  • First Round $35M

    (Jan 2004)

  • Investors Count 6

All 1 funding rounds of Novacea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2004$35MSeries C––
Valuation history

7 investors in total: 7 institutional.

Investors in Novacea

Novacea has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Apax Partners, Transcept Pharmaceuticals and Domain Associates.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Equity investments are focused on tech, services, and consumer sectors.
1981apax.comHong Kong, China
Life science & tech focused VC firm investing in the US
domainvc.comPrinceton, United States
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
versantventures.com
Biotech funding, drug development support, and investment in life sciences.
sofinnova.com
proquestvc.com
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions
1996transcept.comBoston, United States
Premium access

Investor details for Novacea

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Novacea

4 dated milestones of Novacea across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Novacea is founded.
  2. Funding First funding round of $35.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Exit Acquired by Transcept Pharmaceuticals.

Competitors of Novacea

Novacea has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
miragen.com2007Boulder, United States$111.29M92
MicroRNA-based therapeutics are developed for treating multiple diseases.
Premium access

Detailed competitors of Novacea

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Novacea

Websites that share an audience with Novacea (novacea.com).

Similar websites

Websites whose visitors overlap most with Novacea. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
mundipharma.net
mundipharma.net
100%
–
cap-m-quik.com
100%
View details
ventanamed.com
100%
View details
canderm.com
canderm.com
100%
–
viropharma.com
100%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Novacea

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Novacea (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Novacea

Premium access

Complete news archive for Novacea

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Novacea

Novacea was founded in 2001 and raised its 1st funding round 3 years after it was founded.

Novacea is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.

Novacea is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series C of $35M, raised on Jan 2004.

Novacea Pharmaceuticals was established in 2001 in Richmond, United States, within the biotechnology sector. Focus was placed on in-licensing and advancing cancer therapies, including Asentar in phase 3 trials for androgen-independent prostate cancer and phase 2 for advanced pancreatic cancer, as well as AQ4N in phase 1b2a trials for glioblastoma multiforme. Acquisition by Transcept Pharmaceuticals occurred in September 2008, leading to a merger.

Novacea's top competitors include C4 Therapeutics, Erasca and MiRagen.

Novacea has 7 investors. Key investors include Apax Partners, Transcept Pharmaceuticals, Domain Associates, NEA, and Versant Ventures.

Yes. Novacea was acquired by Transcept Pharmaceuticals in September 2008.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available